Literature DB >> 1928186

Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital.

R W Haley1.   

Abstract

To compete more effectively for resources, it is increasingly important for infection control practitioners to estimate the costs of nosocomial infections and the amount of money their infection control programs save the hospital. Studies on costs should estimate both extra length of stay and extra costs attributable to infectious complications. Cost estimates should either adjust charges by a cost to charge ratio, which is relatively easy, or estimate hospital costs directly by detailed cost-accounting, which is comparatively more difficult. If there is insufficient time to measure costs concurrently in every infected patient, comparative studies can be done by comparing infected and uninfected patients matched on characteristics that control for the preexisting differences between them. Diagnosis-related groups and the number of diagnoses appear to be useful matching variables because they are strongly associated with both nosocomial infection and length of stay. The final results should be expressed as either potential or actual savings to the hospital, depending on whether significant reductions in nosocomial infection rates have been achieved.

Entities:  

Mesh:

Year:  1991        PMID: 1928186     DOI: 10.1016/0002-9343(91)90341-t

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  15 in total

Review 1.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

2.  Variation in Resource Utilization for Patients With Hip and Pelvic Fractures Despite Equal Medicare Reimbursement.

Authors:  Andre M Samuel; Matthew L Webb; Adam M Lukasiewicz; Bryce A Basques; Daniel D Bohl; Arya G Varthi; Joseph M Lane; Jonathan N Grauer
Journal:  Clin Orthop Relat Res       Date:  2016-02-25       Impact factor: 4.176

3.  Economical saving due to prophylaxis in the prevention of surgical wound infection.

Authors:  M Fernandez Arjona; R Herruzo Cabrera; F Gomez-Sancha; S Nieto; J Rey Calero
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

4.  Impact of staffing on bloodstream infections in the neonatal intensive care unit.

Authors:  Jeannie P Cimiotti; Janet Haas; Lisa Saiman; Elaine L Larson
Journal:  Arch Pediatr Adolesc Med       Date:  2006-08

Review 5.  Epidemiology, therapy and costs of nosocomial infection.

Authors:  R Gálvez-Vargas; A Bueno-Cavanillas; M García-Martín
Journal:  Pharmacoeconomics       Date:  1995-02       Impact factor: 4.981

6.  The cost effectiveness of amoxicillin/clavulanic acid as antibacterial prophylaxis in abdominal and gynaecological surgery.

Authors:  P G Davey; S E Parker; I K Crombie; M Jaderberg
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

7.  Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients.

Authors:  D Pittet; B Thiévent; R P Wenzel; N Li; G Gurman; P M Suter
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

8.  Surgical site infection in orthopedic trauma: A case-control study evaluating risk factors and cost.

Authors:  Rachel V Thakore; Sarah E Greenberg; Hanyuan Shi; Alexandra M Foxx; Elvis L Francois; Marc A Prablek; Samuel K Nwosu; Kristin R Archer; Jesse M Ehrenfeld; William T Obremskey; Manish K Sethi
Journal:  J Clin Orthop Trauma       Date:  2015-06-18

9.  Salmonella typhimurium outbreak in a neonatal unit in Turkey.

Authors:  Murat Anil; Mehmet Helvaci; Nisel Ozkalay; Esra Toprak; Ayse Berna Anil; Mustafa Dilek; Neval Agus
Journal:  Indian J Pediatr       Date:  2009-04-23       Impact factor: 1.967

10.  [Electronic surveillance of nosocomial infections in head and neck surgery and stapes surgery].

Authors:  S Preyer; A Failenschmid; M Holderried; D Bless
Journal:  HNO       Date:  2005-04       Impact factor: 1.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.